Advertisement
Advertisement

ADXN

ADXN logo

Addex Therapeutics Ltd - ADR

5.95
USD
Sponsored
+0.15
+2.59%
Aug 10, 12:17 UTC -4
Closed
exchange

After-Market

5.63

-0.32
-5.29%

Addex Therapeutics Ltd - ADR Profile

About

Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. The company's lead drug candidate includes dipraglurant, ADX71149 which are in clinical stage. Its Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Addex Therapeutics Ltd is based in Geneva, Switzerland.

Info & Links

CEO

Tim Dyer

Headquarters

CHEMIN DES MINES 9
GENEVA, V8 CH-1202, SWITZERLAND

Industry

Medical Drugs

Sector

Medical

Website

www.addextherapeutics.com

Auditor

BDO AG

Share holders

--

Employees

3

Addex Therapeutics Ltd - ADR Statistics

Valuation Measures

Market Capitalization2

7.13M

Enterprise Value

5.94M

Enterprise Value/EBITDA(ttm)

-1.79

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.70

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

-1326.56%

Return on Equity(ttm)

-134.76%

Return on Invested Capital(ttm)

-145.26%

Return on Assets(ttm)

-106.00%

Income Statement

Revenue(ttm)

36.10K

Revenue Per Share(ttm)

--

Gross Profit(ttm)

36.10K

EBITDA(ttm)3

-3.31M

Net Income Available to Common(ttm)

-8.67M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

1.50

52-Week Change

-26.97%

S&P 500 52-Week Change

21.65%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

--

Dividend Yield

0.00%

Float4

1.05M

% Held by Insiders

15.00%

% Held by Institutions

16.14%

Balance Sheet

Total Cash(mrq)

1.19M

Total Cash Per Share(mrq)

--

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

0.97%

Quick Ratio(mrq)

0.97%

Book Value Per Share(mrq)

4.22

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.99

Free Cash Flow(ytd)

-977.30K

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement